This HTML5 document contains 167 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/kegg-drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/drugbank/
n29http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n23http://www.drugs.com/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/chemspider/
n12http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n19http://www.rxlist.com/cgi/generic/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/bindingdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/pubchem-compound/
n20http://linked.opendata.cz/ontology/sukl/drug/
n21http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00749/identifier/pubchem-substance/

Statements

Subject Item
n2:DB00749
rdf:type
n3:Drug
n3:description
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
n3:dosage
n16:271B5771-363D-11E5-9242-09173F13E4C5 n16:271B5772-363D-11E5-9242-09173F13E4C5 n16:271B5773-363D-11E5-9242-09173F13E4C5 n16:271B5774-363D-11E5-9242-09173F13E4C5 n16:271B5770-363D-11E5-9242-09173F13E4C5 n16:271B577D-363D-11E5-9242-09173F13E4C5 n16:271B577E-363D-11E5-9242-09173F13E4C5 n16:271B5779-363D-11E5-9242-09173F13E4C5 n16:271B577A-363D-11E5-9242-09173F13E4C5 n16:271B577B-363D-11E5-9242-09173F13E4C5 n16:271B577C-363D-11E5-9242-09173F13E4C5 n16:271B5775-363D-11E5-9242-09173F13E4C5 n16:271B5776-363D-11E5-9242-09173F13E4C5 n16:271B5777-363D-11E5-9242-09173F13E4C5 n16:271B5778-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours
n3:indication
For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
n3:manufacturer
n5:271B5755-363D-11E5-9242-09173F13E4C5 n5:271B5756-363D-11E5-9242-09173F13E4C5 n5:271B5761-363D-11E5-9242-09173F13E4C5 n5:271B5762-363D-11E5-9242-09173F13E4C5 n5:271B575F-363D-11E5-9242-09173F13E4C5 n5:271B5760-363D-11E5-9242-09173F13E4C5 n5:271B5765-363D-11E5-9242-09173F13E4C5 n5:271B5763-363D-11E5-9242-09173F13E4C5 n5:271B5764-363D-11E5-9242-09173F13E4C5 n5:271B5759-363D-11E5-9242-09173F13E4C5 n5:271B575A-363D-11E5-9242-09173F13E4C5 n5:271B5757-363D-11E5-9242-09173F13E4C5 n5:271B5758-363D-11E5-9242-09173F13E4C5 n5:271B575D-363D-11E5-9242-09173F13E4C5 n5:271B575E-363D-11E5-9242-09173F13E4C5 n5:271B575B-363D-11E5-9242-09173F13E4C5 n5:271B575C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00749 n22:DB00749
dcterms:title
Etodolac
adms:identifier
n7:3308 n8:46505184 n9:D00315 n10:0228-2599-11 n14:Etodolac n15:PA449550 n24:50016799 n25:DB00749 n26:4909 n27:3192
n3:mechanismOfAction
Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
n3:packager
n5:271B5733-363D-11E5-9242-09173F13E4C5 n5:271B5734-363D-11E5-9242-09173F13E4C5 n5:271B5731-363D-11E5-9242-09173F13E4C5 n5:271B5732-363D-11E5-9242-09173F13E4C5 n5:271B572F-363D-11E5-9242-09173F13E4C5 n5:271B5730-363D-11E5-9242-09173F13E4C5 n5:271B574A-363D-11E5-9242-09173F13E4C5 n5:271B574B-363D-11E5-9242-09173F13E4C5 n5:271B5748-363D-11E5-9242-09173F13E4C5 n5:271B5749-363D-11E5-9242-09173F13E4C5 n5:271B5746-363D-11E5-9242-09173F13E4C5 n5:271B5747-363D-11E5-9242-09173F13E4C5 n5:271B5745-363D-11E5-9242-09173F13E4C5 n5:271B5752-363D-11E5-9242-09173F13E4C5 n5:271B5750-363D-11E5-9242-09173F13E4C5 n5:271B5751-363D-11E5-9242-09173F13E4C5 n5:271B574E-363D-11E5-9242-09173F13E4C5 n5:271B574F-363D-11E5-9242-09173F13E4C5 n5:271B574C-363D-11E5-9242-09173F13E4C5 n5:271B573D-363D-11E5-9242-09173F13E4C5 n5:271B574D-363D-11E5-9242-09173F13E4C5 n5:271B573E-363D-11E5-9242-09173F13E4C5 n5:271B573B-363D-11E5-9242-09173F13E4C5 n5:271B573C-363D-11E5-9242-09173F13E4C5 n5:271B5739-363D-11E5-9242-09173F13E4C5 n5:271B573A-363D-11E5-9242-09173F13E4C5 n5:271B5737-363D-11E5-9242-09173F13E4C5 n5:271B5738-363D-11E5-9242-09173F13E4C5 n5:271B5743-363D-11E5-9242-09173F13E4C5 n5:271B5753-363D-11E5-9242-09173F13E4C5 n5:271B5754-363D-11E5-9242-09173F13E4C5 n5:271B5742-363D-11E5-9242-09173F13E4C5 n5:271B5744-363D-11E5-9242-09173F13E4C5 n5:271B5740-363D-11E5-9242-09173F13E4C5 n5:271B5741-363D-11E5-9242-09173F13E4C5 n5:271B572D-363D-11E5-9242-09173F13E4C5 n5:271B572E-363D-11E5-9242-09173F13E4C5 n5:271B572B-363D-11E5-9242-09173F13E4C5 n5:271B572C-363D-11E5-9242-09173F13E4C5 n5:271B5729-363D-11E5-9242-09173F13E4C5 n5:271B572A-363D-11E5-9242-09173F13E4C5 n5:271B573F-363D-11E5-9242-09173F13E4C5 n5:271B5728-363D-11E5-9242-09173F13E4C5 n5:271B5735-363D-11E5-9242-09173F13E4C5 n5:271B5736-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.
n3:synonym
Etodolaco 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid Etodolsäure Etodolac Etodolacum 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid Étodolac 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid Etodolic acid (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid
n3:toxicity
Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
n3:volumeOfDistribution
* 390 mL/kg
n20:hasAHFSCode
n29:28-08-04-92
n3:foodInteraction
Take with food to reduce gastric irritation. Avoid alcohol. Food increases the peak plasma concentration of extended-release tablets with no effect on extent of absorption. Food increases the time to peak concentration of regular release oral formulations by 1.4 to 3.8 hours with no effect on extent of absorption.
n3:mixture
n13:271B5727-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
> 99% bound, primarily to albumin
n3:synthesisReference
Christopher A. Demerson, Leslie G. Humber, "Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac." U.S. Patent US4585877, issued May, 1977.
foaf:page
n19:etodolac.htm n23:etodolac.html
n3:IUPAC-Name
n4:271B5783-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5789-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5788-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5785-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5786-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5787-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5781-363D-11E5-9242-09173F13E4C5 n4:271B5799-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B577F-363D-11E5-9242-09173F13E4C5 n4:271B5782-363D-11E5-9242-09173F13E4C5 n4:271B579B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5780-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B579C-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:M01AB08
n3:H-Bond-Acceptor-Count
n4:271B578F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5790-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B578A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B578B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B578D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B578C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B578E-363D-11E5-9242-09173F13E4C5
n3:absorption
Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
41340-25-4
n3:category
n3:clearance
* Oral cl=49.1 mL/h/kg [Normal healthy adults] * Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)] * Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)] * Oral cl=45.7 mL/h/kg [Eldery (>65 years)] * Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)] * Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]
n3:containedIn
n17:271B5769-363D-11E5-9242-09173F13E4C5 n17:271B576A-363D-11E5-9242-09173F13E4C5 n17:271B576F-363D-11E5-9242-09173F13E4C5 n17:271B576D-363D-11E5-9242-09173F13E4C5 n17:271B576E-363D-11E5-9242-09173F13E4C5 n17:271B576B-363D-11E5-9242-09173F13E4C5 n17:271B576C-363D-11E5-9242-09173F13E4C5 n17:271B5767-363D-11E5-9242-09173F13E4C5 n17:271B5768-363D-11E5-9242-09173F13E4C5 n17:271B5766-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5795-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5797-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5798-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B579A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5794-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5793-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5796-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5784-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5791-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5792-363D-11E5-9242-09173F13E4C5